- Home
- PMEC vs APRE Comparison
PMEC vs APRE Comparison
Compare PMEC & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMEC
- APRE
- Stock Information
- Founded
- PMEC 1984
- APRE 2006
- Country
- PMEC Singapore
- APRE United States
- Employees
- PMEC N/A
- APRE N/A
- Industry
- PMEC
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PMEC
- APRE Health Care
- Exchange
- PMEC Nasdaq
- APRE Nasdaq
- Market Cap
- PMEC 26.2M
- APRE 13.5M
- IPO Year
- PMEC 2023
- APRE 2019
- Fundamental
- Price
- PMEC $0.78
- APRE $1.87
- Analyst Decision
- PMEC
- APRE Strong Buy
- Analyst Count
- PMEC 0
- APRE 2
- Target Price
- PMEC N/A
- APRE $15.50
- AVG Volume (30 Days)
- PMEC 120.6K
- APRE 21.0K
- Earning Date
- PMEC 12-31-2024
- APRE 05-13-2025
- Dividend Yield
- PMEC N/A
- APRE N/A
- EPS Growth
- PMEC N/A
- APRE N/A
- EPS
- PMEC N/A
- APRE N/A
- Revenue
- PMEC $74,310,000.00
- APRE $1,502,581.00
- Revenue This Year
- PMEC N/A
- APRE N/A
- Revenue Next Year
- PMEC N/A
- APRE N/A
- P/E Ratio
- PMEC N/A
- APRE N/A
- Revenue Growth
- PMEC 3.94
- APRE 157.63
- 52 Week Low
- PMEC $0.49
- APRE $1.85
- 52 Week High
- PMEC $1.13
- APRE $6.70
- Technical
- Relative Strength Index (RSI)
- PMEC 54.44
- APRE 26.70
- Support Level
- PMEC $0.74
- APRE $2.17
- Resistance Level
- PMEC $0.79
- APRE $2.30
- Average True Range (ATR)
- PMEC 0.04
- APRE 0.17
- MACD
- PMEC -0.00
- APRE -0.01
- Stochastic Oscillator
- PMEC 36.11
- APRE 2.50
About PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.